Michael Sapienza, Chief Executive Officer of the Colorectal Cancer Alliance, shared a post on LinkedIn:
“Breakthroughs in colorectal cancer often start by looking beyond the tumor itself and asking better questions about the systems around it.
That is what Project Cure CRC scientist Lisa Mielke has done in her latest published research. Her work focuses on neuropeptides, the signaling molecules released by nerves in the gut, and how they may influence tumor growth.
It is a meaningful shift in perspective that expands how we think about the disease, moving from a narrow focus on cancer cells to a broader understanding of the tumor microenvironment and its connections to the nervous and immune systems.
The Colorectal Cancer Alliance’s work through Project Cure CRC is creating new possibilities for treatment. By identifying how these signaling pathways work, scientists may be able to repurpose existing therapies and develop more targeted approaches for CRC patients.
The future of colorectal cancer care will be defined by insights like these that expand the field and move us closer to more effective, more precise interventions.
Project Cure CRC proves that investing in bold, early stage research can shape the next generation of treatments. Please support the Alliance and its work to end this disease.
Read more about Dr. Mielke’s research.”
Other articles about CRC on OncoDaily.